The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
Open accessAbstract
The macrolide antibiotic azithromycin (CP-62,993; 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A; also designated XZ-450 [Pliva Pharmaceuticals, Zagreb, Yugoslavia]) showed a significant improvement in potency against gram-negative organisms compared with erythromycin while retaining the classic erythromycin spectrum. It was up to four times more potent than erythromycin against Haemophilus influenzae and Neisseria gonorrhoeae and twofold more potent against Branhamella catarrhalis, Campylobacter species, and Legionella species. It had activity similar to that of erythromycin against Chlamydia spp. Azithromycin was significantly more potent versus many genera of the family Enterobacteriaceae; its MIC for 90% of strains of Escherichia, Salmonella, Shigella, and Yersinia was less than or equal to 4 micrograms/ml, compared with 16 to 128 micrograms/ml for erythromycin. Azithromycin inhibited the majority of gram-positive organisms at less than or equal to 1 micrograms/ml. It displayed cross-resistance to erythromycin-resistant Staphylococcus and Streptococcus isolates. It had moderate activity against Bacteroides fragilis and was comparable to erythromycin against other anaerobic species. Azithromycin also demonstrated improved bactericidal activity in comparison with erythromycin. The mechanism of action of azithromycin was similar to that of erythromycin since azithromycin competed effectively for [14C]erythromycin ribosomebinding sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Holdeman, L. V., Moore, W. E., & Cato, E. P. (1977) · Cited by 2,988
Antibiotic sensitivity testing. Report of an international collaborative study.
Ericsson, H., & Sherris, J. C. (1971) · PubMed · Cited by 1,324
An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics.
Steers, E., Foltz, E. L., & GRAVES, B. S. (1959) · PubMed · Cited by 1,063
Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A., Haskell, S. L., & Retsema, J. A. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1948 · Cited by 321
Self-citationAltered Methylation of Ribosomal RNA in an Erythromycin-Resistant Strain of Staphylococcus aureus
Lai, C. J., & Weisblum, B. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.856 · Cited by 274
George, W. L., Sutter, V. L., & Finegold, S. M. (1978) · Current Microbiology · doi:10.1007/bf02601709 · Cited by 123
Sulbactam/Ampicillin: In Vitro Spectrum, Potency, and Activity in Models of Acute Infection
Retsema, J. A., English, A. R., Girard, A., Lynch, J. E., ANDERSON, M. R., Brennan, L. A., Cimochowski, C. R., FAIELLA, J. A., Norcia, W., & Sawyer, P. S. (1986) · Clinical Infectious Diseases · doi:10.1093/clinids/8.supplement_5.s528 · Cited by 105
Self-citationEnglish, A. R., Retsema, J. A., Girard, A., Schelkly, W., & Lynch, J. E. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.1.118 · Cited by 7
Self-citation
Cited by
Pankey, G. A., & Sabath, L. D. (2004) · Clinical Infectious Diseases · doi:10.1086/381972 · Cited by 1,201
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600350 · Cited by 672
Targeting Antibiotic Resistance
Chellat, M. F., Raguž, L., & Riedl, R. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201506818 · Cited by 487
The macrolide antibiotic renaissance
Dinos, G. P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13936 · Cited by 471
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
French, G. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl393 · Cited by 441
A platform for the discovery of new macrolide antibiotics
Seiple, I. B., Zhang, Z., Jakubec, P., Langlois-Mercier, A., Wright, P. M., Hog, D. T., Yabu, K., Allu, S. R., Fukuzaki, T., Carlsen, P. N., et al. (2016) · Nature · doi:10.1038/nature17967 · Cited by 351
Girard, A. E., Girard, D., English, A. R., Gootz, T. D., Cimochowski, C. R., Faiella, J. A., Haskell, S. L., & Retsema, J. A. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1948 · Cited by 321
Self-citationPeters, D. H., Friedel, H. A., & McTavish, D. (1992) · Drugs · doi:10.2165/00003495-199244050-00007 · Cited by 304
The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms
Zimmermann, P., Ziesenitz, V. C., Curtis, N., & Ritz, N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00302 · Cited by 303
Macrolide antibiotics for cystic fibrosis
Southern, K. W., Barker, P. M., Solis-Moya, A., & Patel, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002203.pub4 · Cited by 298
The Macrolides: Erythromycin, Clarithromycin, and Azithromycin
Alvarez-Elcoro, S., & Enzler, M. J. (1999) · Mayo Clinic Proceedings · doi:10.4065/74.6.613 · Cited by 282
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Hoffmann, N., Lee, B., Hentzer, M., Rasmussen, T. B., Song, Z., Johansen, H. K., Givskov, M., & Høiby, N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01011-06 · Cited by 267
Erythromycin inhibits the assembly of the large ribosomal subunit in growing Escherichia coli cells
Chittum, H. S., & Champney, W. S. (1995) · Current Microbiology · doi:10.1007/bf00295501 · Cited by 88
“However, azithromycin, a novel 15-membered erythromycin derivative [34, 47], was as effective as erythromycin in inhibiting subunit assembly (Fig.”
Background
Metadata
- Authors
- Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., Borovoy, R., Brennan, L., & Mason, R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1987-12
- Volume
- 31
- Issue
- 12
- Pages
- 1939-1947
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2105872313
- Cited by
- 464
- References
- 8
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.